Alagebrium (formerly known as ALT-711) was a drug candidate developed by Alteon Corporation. It was the first drug candidate to be clinically tested for the purpose of breaking the crosslinks caused by advanced glycation endproducts (AGEs) thereby reversing one of the main mechanisms of aging.
This page contains content from the copyrighted Wikipedia article "Alagebrium"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
